Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder

Mehrian Jafarizade1, Kiran Goli1, Vivette D’Agati2, Essel Dulaimi3, Krupa Daniel4, Bradley Lash5, and Sharon Maynard1

1Department of Medicine, Division of Nephrology, Lehigh Valley Health Network, Allentown, PA, 2Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 3Department of Anatomic Pathology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 4Department of Geriatrics and Extended Care, VA Medical Center, Coatesville, PA, and 5Lehigh Valley Cancer Institute, Lehigh Valley Health Network, Allentown, PA, USA

Abstract. Introduction: Plasmablastic lymphoma (PBL) is a rare form of B-cell lymphoma which was first described in 1997. Sixteen cases of highly malignant diffuse large B-cell lymphoma (DLBCL) were reported in the oral cavity with distinctive immunohistological features that distinguished it from other B-cell lymphomas, including negative immunoreactivity for CD20. In 2008, PBL was classified as a separate category by the World Health Organization (WHO) [3].

PBL was first described as an HIV-associated lymphoma. Shortly thereafter, cases of PBL were reported in the setting of other immunosuppressed states, such as autoimmune disorders and solid organ transplantation. In patients with HIV, PBL most often originates from the oral cavity. In case reports of PBL in non-HIV patients, PBL originates from other sites such as the retroperitoneum, gastrointestinal (GI) tract, and lungs [4, 5, 6, 7]. PBL involving the urinary tract is extremely unusual, and renal failure in association with PBL is rarely reported [8].

Kidney impairment in lymphoma can be directly related to malignancy such as obstruction of the ureters or renal vasculature by tumor or neoplastic infiltration of renal parenchyma. Alternatively, kidney injury can be caused by indirect effects of lymphoma such as hypercalcemia, paraproteinemia, immune-mediated glomerulonephritis (GN), and amyloidosis. Treatment-related complications include tumor lysis syndrome, chemotherapy-induced renal failure, and radiation nephritis [9]. In clinical practice, renal failure is often due to a combination of these factors. Prompt diagnosis and treatment are needed to prevent kidney damage.

Herein, we present a case of acute kidney injury (AKI) due to light chain cast nephropathy (LCCN) associated with PBL of the bladder. LCCN is a rare complication of lymphoma, and this case represents the first clinical report of LCCN in PBL.

Case presentation

A 39-year-old African American female with 20-year history of HIV infection and...
Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder

Hypertension presented with complaints of abdominal pain and decreased urinary output of 2 weeks duration. She had sustained a mechanical fall 2 weeks prior to presentation and had taken ibuprofen for pain control. Initial evaluation revealed a serum creatinine 5.5 mg/dL. Her baseline serum creatinine 3 months prior to presentation was 0.91 mg/dL. Urinalysis showed 3+ proteinuria and microhematuria, without microscopic casts. Urine protein-to-creatinine ratio was > 10 g/g. CD4 count was 267/µL and HIV viral load by PCR revealed viremia with 1,220 copies/mL. She was compliant with antiretroviral therapy (ART) consisting of bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy), and lisinopril 10 mg daily for hypertension.

Non-contrast computed tomography (CT) scan of the abdomen and pelvis showed mild bilateral hydronephrosis, marked diffuse irregular bladder wall thickening and ascites. Bladder cystoscopy revealed no evidence of ureteral obstruction but showed diffuse nodules throughout the bladder wall; multiple bladder biopsies were obtained. Given her renal insufficiency, tenofovir was stopped and ART was changed to renally adjusted dolutegravir, rilpivirine, and lamivudine. Serologic workup, including

Figure 1. Plasmablastic lymphoma of the bladder. A: Transurethral bladder resection specimen. Intact urothelial mucosa with underlying hypercellular tumor infiltrating muscularis propria (H & E, × 10). B: Large plasmablastic cells with prominent eosinophilic nucleoli present in sheets, with frequent apoptotic bodies and mitotic figures (H & E, × 100). C: CD138 is expressed in lymphoma cells as well as the benign urothelial surface (× 10). Tumor cell stain diffusely positive for κ, negative for λ (inset, both × 100). D: Ki 67 demonstrated very high proliferation index approaching 100% (× 10).
complement C3 and C4, antinuclear antibodies, hepatitis C antibody, hepatitis B surface antigen, anti-neutrophil cytoplasmic autoantibody (ANCA) titers, and anti-GBM antibody, were negative. Serum protein electrophoresis was consistent with acute inflam-
light chain cast nephropathy caused by plasmablastic lymphoma of the bladder

Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder

Inflammatory stress response, with no evidence for a monoclonal protein. However, serum free κ light chains were elevated at 1.988 mg/L, with serum free κ/λ ratio 36.4. Urine immunofixation revealed monoclonal free κ light chains. Attempted bone marrow biopsy was unsuccessful. Diagnostic paracentesis was negative for malignancy. Hemodialysis was initiated on hospital day 6 because of progressive renal failure and uremic symptoms.

Bladder biopsy revealed high-grade plasmablastic lymphoma (Figure 1). Histopathology showed large plasmablastic cells diffusely positive for CD138, MUM-1, and negative for PAX-5, CD20, BCL-6, and BCL-2. Cell proliferation marker Ki-67 approached 100%. Tumor cells were positive for EBER1. Additional immunostains revealed that the plasmablastic lymphoma cells were κ light chain-restricted and positive for CD56, CD10, and c-MYC. They were negative for λ light chain, CD30, and AE1/AE3.

Diagnostic kidney biopsy, performed 9 days after presentation, revealed focal atypical κ-restricted tubular casts with diffuse acute tubular injury and 30% interstitial inflammation and edema, consistent with κ light chain cast nephropathy (Figure 2). There was no evidence of glomerular disease by light microscopy, immunofluorescence, or electron microscopy.

Chemotherapy was initiated 2 weeks after initial presentation with bortezomib and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). She received 1 dose of intrathecal methotrexate, cytarabine, and hydrocortisone followed by 3 doses of intrathecal methotrexate alone to prevent central nervous system (CNS) relapse, which is common in patients with HIV-associated lymphoma [10]. She was maintained on ART during this period and started on trimethoprim-sulfamethoxazole and acyclovir for opportunistic infection prophylaxis.

Seven weeks after initial presentation, renal function recovered, and hemodialysis was discontinued. Eleven weeks after presentation, the patient achieved complete remission by imaging (PET). Her chemotherapeutic induction regimen was then switched to bortezomib with ifosfamide, carboplatin, and etoposide (ICE) as CHOP is considered insufficient treatment for PBL [11]. Six months after presentation, repeat bladder biopsy showed no evidence of PBL and additional testing including PET and bone marrow biopsy were negative confirming complete remission. Seven months after presentation, she underwent modified BEAM (BCNU, etoposide, cytarabine, melphalan) followed by autologous hematopoietic cell transplant. At last follow-up 8 months after autologous hematopoietic cell transplant, her renal function remains stable (creatinine 1.07 mg/dL) with minimal proteinuria (urine protein-to-creatinine ratio 0.36 g/g), normal plasma free light chains, and improved HIV viral load (364 copies/mL). She tolerated chemotherapy well, except for peripheral neuropathy and onychodystrophy which were attributed to her chemotherapy.

Discussion

PBL is a rare, aggressive variant of DLBCL associated with HIV infection and immunosuppression. PBL accounts for less than 0.2% of all the lymphoid malignancies in the United States [12] and ~ 2% of HIV-associated lymphomas [13]. Strong male predominance of 4 : 1 has been noted in HIV-associated PBL, with lower ratio in non-HIV-associated PBL [11, 14, 15].

PBL typically contains immunoblastic or plasmablastic tumor cells with varying degrees of plasmacytic differentiation. Malignant cells have abundant cytoplasm with eccentric nuclei and prominent nucleoli. PBL cells are immunophenotypically distinct, expressing plasma cell markers including MUM1/IRF-4, CD38, and CD138 and lacking pan-B cell markers CD20 and CD79. Epstein-Barr virus (EBV)-encoded RNA (EBER1) is usually positive in PBL, as in this case [16]. Light chain restriction is a common finding in PBL [17]. In this case, the immunohistochemical pattern of 100% Ki-67 staining, and positivity for CD10, EBER, and c-MYC in the setting of HIV suggest this was PBL and not an extra-medullary plasmacytoma [18].

Although initial cases of PBL were predominantly reported in patients with HIV, subsequently PBL has been reported in recipients of organ transplants [11] and other immunosuppressed populations. [19] Solid organ transplant recipients are at increased
risk for post-transplant PBL and EBV-related lymphoma secondary to chronic immunosuppressive therapy to prevent graft rejection. Post-transplant PBL is most often reported in kidney and heart transplant recipients [20]. Unlike diffuse large B-cell lymphoma, PBL usually presents in extra-nodal sites, most commonly the oral cavity, GI tract, and skin. Approximately 40% present with bone marrow involvement and B symptoms like fevers, weight loss, and night sweats [11]. Atypical extra nodal distribution of PBL can occur as orbital, adrenal, pleuropulmonary, paraspinal, and gonadal involvement [21, 22, 23]. PBL leading to hydronephrosis due to direct urinary tract involvement is exceedingly rare [8, 24, 25]. Only one prior case of bladder PBL has been reported to date [8]. The site of extra-medullary disease does not have a consistent impact on survival or prognosis, although disease limited to oral cavity may have a better prognosis [26]. Vigilance is required for the development of circulating monoclonal immunoglobulins, as occurred in this case, which can cause kidney injury.

AKI in our patient was initially presumed to be secondary to obstructive uropathy. However, cystoscopy revealed no evidence of ureteral obstruction except for subtle calyceal fullness. The differential diagnosis for our patient’s AKI after the pathologic diagnosis of PBL had been established was broad. Our patient had been exposed to ibuprofen, a nonsteroidal anti-inflammatory (NSAID), prior to admission. NSAIDs predispose to ischemic acute tubular injury by inhibiting prostaglandin-mediated afferent vasoconstriction, reducing peritubular blood flow. NSAIDs can also cause acute interstitial nephritis and nephrotic-range proteinuria with minimal change disease [27]. Our patient had longstanding HIV treated with tenofovir alafenamide (TAF). TAF is a prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor. Although TAF is less nephrotoxic than its predecessor prodrug tenofovir disoproxil fumarate (TDF), it can cause proximal tubule mitochondrial dysfunction and AKI [28]. Another diagnostic possibility in our patient was HIV-associated nephropathy.

| Variable                          | On presentation | 6 days after presentation (dialysis initiation) | 6 months after presentation | Reference range                      |
|-----------------------------------|-----------------|-----------------------------------------------|----------------------------|--------------------------------------|
| White blood cell count            | 10,700/mm³      | 8,700/mm³                                     | 6,500/mm³                  | 4,000 – 10,000/mm³                   |
| Hemoglobin                        | 10.2 g/dL       | 9.1 g/dL                                      | 12.1 g/dL                  | 11.5 – 14.5 g/dL                     |
| Platelet count                    | 470,000/mm³     | 489,000/mm³                                   | 336,000/mm³                | 140,000- 350,000/mm³                |
| Blood urea nitrogen               | 27 mg/dL        | 42 mg/dL                                      | 19 mg/dL                   | 7 – 25                               |
| Creatinine                        | 5.55 mg/dL      | 11.36 mg/dL                                   | 1.05 mg/dL                 | 0.80 – 1.20 mg/dL                    |
| HIV-1 RNA                         | –               | 1,220 copies/mL                               | 1,030 copies/mL            | < 20 copies/mL                       |
| CD4 T-cell count                  | 267/µL          | 134/µL                                        | 401 – 1532/µL              |
| Aspartate aminotransferase        | 39 U/L          | 15 U/L                                        | 13 – 39 U/L                |
| Alanine transaminase              | 21 U/L          | 27 U/L                                        | 7 – 52 U/L                 |
| Total Bilirubin                   | 0.3 mg/dL       | –                                             | 0.4 mg/dL                  | 0.2 – 1.1 mg/dL                      |
| Total protein                     | 7.1 g/dL        | –                                             | 9.0 g/dL                   | 6.4 – 8.9 g/dL                       |
| Creatinine kinase                 | 33 U/L          | –                                             | 30 – 223 U/L               |
| Uric acid                         | –               | 10.6 mg/dL                                    | –                          | 2.8 – 9.1 mg/dL                      |
| Lactate dehydrogenase             | –               | 510 U/L                                       | 164 U/L                    | 140 – 271 U/L                        |
| Spot urine protein to creatinine ratio | 10 g/g        | 0.48 g/g                                      | < 0.15 g/g                 |
| Serum Ig A                        | –               | 283 mg/dL                                     | 324 mg/dL                  | 83 – 407 mg/dL                       |
| Serum Ig G                        | –               | 1109 mg/dL                                    | 1513 mg/dL                 | 680 – 1,445 mg/dL                    |
| Serum Ig M                        | –               | 52 mg/dL                                      | 53 mg/dL                   | 34 – 214 mg/dL                       |
| Serum protein electrophoresis     | –               | No monoclonal protein                         | No monoclonal protein      | No monoclonal protein                |
| Serum free light chains           | –               | 1,888 mg/dL                                   | 42 mg/dL                   | 3.30 – 19.40 mg/dL                   |
| κ free light chains               | –               | 55 mg/dL                                      | 25 mg/dL                   | 5.7 – 26.30 mg/dL                    |
| λ free light chains               | –               | 36.43                                         | 1.69                       | 0.26 – 1.65                          |
| κ : λ free light chain ratio      | –               | Positive for monoclonal κ free light chain    | –                          | negative                             |
| Urine immunofixation              | –               | Positive for monoclonal κ free light chain    | –                          | negative                             |

Table 1. Laboratory parameters at diagnosis and follow-up.
Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder

(HIVAN) due to collapsing focal segmental glomerulosclerosis (FSGS), although this lesion has become less common in the era of effective antiviral therapies [29, 30]. The most common causes of kidney disease in patients with HIV on ART include immune complex glomerulonephritis (ICGN), diabetic nephropathy, tenofovir nephrotoxicity, and FSGS. HIVAN remains the leading cause of kidney disease in patients not on ART [31].

Finally, the presence of elevated free κ light chains in the urine raised the possibility of a kidney lesion related to her lymphoma. There are no published studies of kidney pathology in patients with plasmablastic lymphoma. However, kidney biopsy studies in patients with non-Hodgkin’s lymphoma have revealed various pathologies including lymphomatous infiltration, membranoproliferative GN, cryoglobulinemic GN, crescentic GN, membranous nephropathy, minimal change disease, immunotactoid GN, AL amyloidosis, cast nephropathy, light chain proximal tubulopathy, and intracapillary monoclonal deposits [32, 33]. In addition to establishing the diagnosis, kidney biopsy is helpful to determine prognosis and predict response to therapy; for example, the extent of cast formation and degree of interstitial fibrosis and tubular atrophy indicate prognosis in patients with light chain cast nephropathy [34]. The broad differential diagnosis in the setting of nephrotic-range proteinuria and worsening kidney function justified the decision to pursue kidney biopsy in our patient.

Kidney biopsy in this case showed acute tubular injury, interstitial inflammation, and κ LCCN. AKI due to LCCN was initially described in patients with multiple myeloma, and later was described in patients with lymphoma [35]. LCCN is the most common tubulointerstitial lesion associated with circulating monoclonal light chains. The diagnostic histopathologic finding is the presence of angulated crystalline casts of monoclonal light chain within tubular lumina [36]. AKI occurs when immunoglobulin light chains in the tubular filtrate bind to uromodulin and produce casts, causing tubular obstruction and renal tubular epithelial cell injury [37]. Tubular degenerative changes are common in LCCN, resembling acute tubular necrosis. Interstitial edema and inflammation are also common features [38].

In our patient, NSAID use, hyperuricemia, tenofovir exposure, and volume depletion may have contributed to the development of kidney injury. NSAIDs and volume depletion attenuate renal perfusion pressure and increase tubular protein concentration, affecting the interaction between uromodulin and light chains and increasing the risk of cast formation [35]. Other factors that may increase risk of cast nephropathy include high levels of urinary free light chains, iodinated contrast, hypercalcemia, and acute pyelonephritis [39].

Recently, monoclonal immunoglobulin-associated kidney diseases have become better defined. Monoclonal gammopathies are diagnosed when monoclonal immunoglobulin (MIg) is identified in the serum or urine resulting from a clonal proliferation of plasma cells or B lymphocytes. Most kidney diseases associated with MIg are a result of MIg or its light or heavy chain deposition in various compartments of the kidney. A variety of hematologic disorders are associated with MIg-kidney disease, including plasma cell dyscrasias and B-cell lymphoproliferative disorders. The term monoclonal gammopathy of renal significance (MGRS) is reserved for a non-malignant but clonal hematologic disorder that results in MIg-associated kidney disease. Clinical presentation can provide a clue to underlying diagnosis; however, kidney biopsy is required for definitive diagnosis [33].

While LCCN is a common cause of AKI in multiple myeloma [40], it should also be suspected in patients without multiple myeloma who have monoclonal protein detected in the urine or an abnormal serum free light chain ratio [41], as in our patient. We believe our patient’s bladder PBL was the source of LCCN because of κ-restricted staining of tubular casts on kidney biopsy, κ-restricted staining of bladder tumor cells, and the presence of κ free light chains in the
urine. LCCN has rarely been reported in association with B-cell lymphomas [35, 42, 43]. To our knowledge, the current case is the first report of cast nephropathy caused by light chain-secreting PBL.

We did not use extracorporeal methods (e.g., therapeutic plasma exchange) for light chain removal in our patient, instead opting for appropriate chemotherapy. There is no data to guide the use of extracorporeal therapies for LCCN in patients with lymphoma. In patients with LCCN due to multiple myeloma, the use of extracorporeal therapies for removal of light chains is controversial, and a benefit has not been clearly established in clinical trials [44, 45, 46, 47]. If utilized, extracorporeal treatment must always be used along with appropriate chemotherapy which is essential in reducing the rate of light chain production.

Prompt diagnosis and treatment to reduce serum free light chains are crucial for optimal renal recovery [40]. PBL generally carries a poor prognosis regardless of HIV status, with survival ranging from 7 to 11 months in different risk groups [11]. More recent data from the Lymphoma Study Association (LYSA) and the Surveillance, Epidemiology, and End Results (SEER) database showed better survival in patients treated with modern chemotherapy regimens, as used in our case [26, 48].

## Conclusion

In summary, we report a case of severe AKI due to light chain cast nephropathy in the setting of plasmablastic lymphoma of the bladder in a patient with chronic HIV infection on ART. Kidney biopsy should be performed in patients with HIV and unexplained AKI for prompt diagnosis and appropriate treatment. Our patient achieved complete hematologic and renal remissions with bortezomib-based chemotherapy followed by autologous hematopoietic cell transplant.

## Funding

The authors received no specific funding for this work.

## Conflict of interest

None pertaining to this case report.

## References

[1] Deleclus HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, Huhn D, Schmidt-Westhausen A, Reichart PA, Gross U, Stein H. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997; 89: 1413-1420. CrossRef PubMed

[2] Al Shaarani M, Shackelford RE, Master SR, Mills GM, AlZubaidi Y, Mamilly A, Wei EX. Plasmablastic lymphoma, a rare entity in bone marrow with unusual immunophenotype and challenging differential diagnosis. Case Rep Hematol. 2019; 2019: 1586328. CrossRef PubMed

[3] Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zehnder AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390. CrossRef PubMed

[4] Takahashi Y, Saiga I, Fukushima J, Seki N, Sagimoto N, Hori A, Eguchi K, Fukusato T. Plasmablastic lymphoma of the retroperitoneum in an HIV-negative patient. Pathol Int. 2009; 59: 968-873. CrossRef PubMed

[5] Wang HW, Yang W, Sun JZ, Lu JY, Li M, Sun L. Plasmablastic lymphoma of the small intestine: case report and literature review. World J Gastroenterol. 2012; 18: 6677-6681. CrossRef PubMed

[6] Cao C, Liu T, Lou S, Liu W, Shen K, Xiang B. Unusual presentation of duodenal plasmablastic lymphoma in an immunocompetent patient: A case report and literature review. Oncol Lett. 2014; 8: 2539-2542. CrossRef PubMed

[7] Chuah KL, Ng SB, Poon L, Yap WM. Plasmablastic lymphoma affecting the lung and bone marrow with CD10 expression and t(8;14)(q24;q32) translocation. Int J Surg Pathol. 2009; 17: 163-166. CrossRef PubMed

[8] Tille JC, Pelte MF, Schwartz J, Dietrich PY, McKee TA. Plasmablastic lymphoma clinically presenting in the urinary tract. Ann Diagn Pathol. 2012; 16: 219-223. CrossRef PubMed

[9] Coggins CH. Renal failure in lymphoma. Kidney Int. 1980; 17: 847-855. CrossRef PubMed

[10] Barra SK, Joshi J, Mounier N, Xue X, Wang D, Ribera J-M, Navarro J-T, Hoffmann C, Duncavage K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA. Central nervous system involvement in AIDS-related lymphomas. Br J Haematol. 2016; 173: 857-866. CrossRef PubMed

[11] Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018; 8: 63-70. CrossRef PubMed

[12] Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66: 443-459. CrossRef PubMed

[13] Zace T, Playsnabh MS, Seguin R, Kudova E, Kasmila B, Kasonkanji E, Tomoka T, Dhungel BM, Mulenga M, Chikasema M, Tewete B, Ntagwanika A, Chiyoyo S, Chimizmu F, Kampci C, Krysiak R, Montgomery ND, Fedorov Y, Gopal S. Plasmablastic lymphoma in Malawi. Infect Agent Cancer. 2018; 13: 22. CrossRef PubMed
Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder

[14] Castillo J, Pantanowitz L, Dezső BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008; 83: 804-809. CrossRef PubMed

[15] Han X, Duan M, Hu L, Zhou D, Zhang W. Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis. Medicine (Baltimore). 2017; 96: e5981. CrossRef PubMed

[16] Sukswai N,Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020; 52: 53-67. CrossRef PubMed

[17] Boy SC, van Heerden MB, Raubenheimer EJ, van Heerden WF. Plasmablastic lymphomas with light chain restriction – plasmablastic extramedullary plasmacytomas? J Oral Pathol Med. 2010; 39: 435-439. PubMed

[18] Vega F, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. Ann Diagn Pathol. 2005; 9: 340-350. CrossRef PubMed

[19] Radresha AH, Lakshmaiah KC, Agarwal A, Babu KG, Loknatha D, Jacob IA, Babu S, Lokesh KN, Rajeev EK. Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: Experience at a regional cancer centre in India. South Asian J Cancer. 2017; 6: 69-71. CrossRef PubMed

[20] Morscio J, Diericks D, Nijs J, Verhoef G, Bitton E, Vanoeveren X, Wlodarska I, Sagaert X, Tousseyn T. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014; 38: 875-886. CrossRef PubMed

[21] Bishnu S, Banerjee S, Bandyopadhyay D, Samui S, Bhattacharya S, Bose D. Plasmablastic lymphoma in HIV patients: Experience at a tertiary care hospital in eastern India. Indian J Cancer. 2015; 52: 563-567. CrossRef PubMed

[22] Schichman SA, McClure R, Schafer RF, Mehta P. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. Am J Hematol. 2004; 77: 291-295. CrossRef PubMed

[23] Sugimoto K, Koike H, Esa A. Plasmablastic lymphoma of the right testis. Int J Urol. 2011; 18: 85-86. PubMed

[24] Cazauret T, Sanches L, Laurent G, Costa K, Vallantin X, Pascale-Ortiz D. Interesting image. Assessment of plasmablastic lymphoma by F-18 FDG PET/CT: case report. Clin Nucl Med. 2010; 35: 882-883. CrossRef PubMed

[25] Yamamoto S, Yasuda Y, Sakai Y. Plasmablastic lymphoma presenting as a ureretal polypoid mass. Indian J Urol. 2018; 34: 152-154. PubMed

[26] Florindex JA, Alderuccio JP, Reis IM, Lossos IS. Survival analysis in treated plasmablastic lymphoma patients: a population-based study. Am J Hematol. 2020; 95: 1344-1351. CrossRef PubMed

[27] Perazaleta MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009; 4: 1275-1283. CrossRef PubMed

[28] Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. Medicine (Baltimore). 2017; 96: e8046. CrossRef PubMed

[29] Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chène G. Groupe D’Épidémiologie Clinique du Sida en Aquitaine (Gecsa). Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS One. 2013; 8: e66223. CrossRef PubMed

[30] Heron JE, Bagnis CI, Gracey DM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther. 2020; 17: 11. CrossRef PubMed

[31] Kadose S, Santoriello D, Bombach AS, Stokes MB, Batata I, Markowitz GS, Wyatt CM, D’Agati VD. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 2020; 97: 1006-1016. CrossRef PubMed

[32] Li SJ, Chen HP, Chen YH, Zhang LH, Tu YM, Liu ZH. Renal involvement in non-Hodgkin lymphoma: proven by renal biopsy. PLoS One. 2014; 9: e95190. CrossRef PubMed

[33] Sethi S, Rajkumar SV, D’Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018; 29: 1810-1823. CrossRef PubMed

[34] Royal V, Leung N, Trowanov S, Naar SH, Écotière L, LeBlanc R, Adam BA, Angioi A, Alexander MP, Assnis AM, Barreca A, Bianco P, Cohen C, Drosou ME, Fatima H, Fenoglio R, Goujon F, Goujon JM, Herrera GA, Knebelmann B, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020; 135: 1833-1846. CrossRef PubMed

[35] Pérez NS, Garcia-Herrera A, Rosiñoł L, Palos I, Santiago E, Espinosa G, Solé M, Campistol JM, Quintana LF. Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant. 2012; 27: 450-453. CrossRef PubMed

[36] Sanders PW. Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol. 2012; 23: 1777-1781. CrossRef PubMed

[37] Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991; 324: 1845-1851. CrossRef PubMed

[38] Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013; 24: 1519-1527. CrossRef PubMed

[39] Markowitz GS. Dysproteinemia and the kidney. Adv Anat Pathol. 2004; 11: 49-63. CrossRef PubMed

[40] Baznayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011; 79: 1289-1301. CrossRef PubMed

[41] Hogan JJ, Alexander MP, Leung N. Dysproteinemia and the kidney: Core Curriculum 2019. Am J Kidney Dis. 2019; 74: 822-836. CrossRef PubMed

[42] Luan H, Wang C, Xing X, Shao L. Cast nephropathy associated with monoclonal immunoglobulin M-secreting mucosa-associated lymphoid tissue
B-cell lymphoma. Clin Nephrol. 2019; 91: 380-385. CrossRef PubMed

[43] Chauvet S, Bridoux F, Ecotière L, Javaugue V, Sirac C, Arnulf B, Thierry A, Quellard N, Milin S, Bender S, Gionjon JM, Jaccard A, Fermand JP, Touchard G. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. Am J Kidney Dis. 2015; 66: 756-767. CrossRef PubMed

[44] Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Goujon JM, Jaccard A, Moulin B, Knebelmann B, et al; MYRE Study Group. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: A randomized clinical trial. JAMA. 2017; 318: 2099-2110. CrossRef PubMed

[45] Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019; 6: e217-e228. CrossRef PubMed

[46] Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011; 364: 2365-2366. CrossRef PubMed

[47] Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN; Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143: 777-784. CrossRef PubMed

[48] Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, Mercier M, Dupuis J, Bijou F, Herbaux C, Delmer A, Fahani B, Besson C, Le Gouill S, Gyan E, Laurent C, Ghesquieres H, Cartron G. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017; 28: 843-848. CrossRef PubMed